Key result
Renal denervation lowers systolic blood pressure by ~20 mmHg at 12 months in resistant hypertension.
Why the study?
Long-term real-world data on the durability and safety of renal sympathetic denervation beyond the first year, particularly from the Middle East, remain limited.
Does renal sympathetic denervation reduce blood pressure in patients with resistant hypertension?
Cohort (n=105)
No
Does renal sympathetic denervation reduce blood pressure in patients with resistant hypertension?
Mean Difference: -20.1
Absolute Event Rate: 142% vs 162.1%
p-value: p=<0.001
In a real-world Middle Eastern cohort, renal denervation provided durable and clinically meaningful blood pressure reductions up to 30 months in patients with resistant hypertension, without requiring systematic medication escalation.
Supports durable BP reductions with renal denervation in resistant hypertension; extends prior RCTs to a real-world cohort but should not yet change practice.
Renal sympathetic denervation (RDN) has demonstrated blood pressure-lowering efficacy in randomized trials; however, long-term real-world data on durability and safety beyond the first year, particularly from the Middle East, remain limited. We conducted a single-center observational cohort study of consecutive patients with resistant hypertension undergoing RDN between February 2023 and December 2025. Baseline blood pressure was defined as the mean of three measurements obtained at separate visits. Follow-up data were collected during routine clinical visits up to 30 months. The primary outcome was durability of blood pressure reduction. Secondary outcomes included changes in antihypertensive medications and renal safety. A total of 105 patients were included. Mean systolic blood pressure decreased from 162.1 ± 18.3 mmHg at baseline to 142.0 ± 18.9 mmHg at 12 months (-20.1 mmHg; p < 0.001), with sustained reductions observed through 30 months. Responder rates remained consistently high. Medication escalation was uncommon (6.7%), and most patients had no increase in antihypertensive burden. Renal function remained stable, with no clinically meaningful changes in creatinine or estimated glomerular filtration rate and no major procedure-related complications. In this real-world cohort, RDN was associated with durable blood pressure reduction over 30 months, achieved without systematic medication intensification and with preserved renal safety, supporting its effectiveness in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Alansari et al. (2026) conducted a cohort in Resistant hypertension (n=105). Renal sympathetic denervation vs. Baseline was evaluated on Change in systolic blood pressure from baseline to 12 months (MD -20.1 mmHg, p=<0.001). Renal denervation significantly reduced mean systolic blood pressure by 20.1 mmHg at 12 months compared to baseline in patients with resistant hypertension, with sustained reductions up to 30 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: